文献速递肺结节与肺癌

早期非小细胞肺癌放疗后心血管毒性风险与肿瘤侧别的关系

Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.
PubMed 文献 · Chest · 2022-01-19

基于SEER-Medicare数据库分析3,256例淋巴结阴性I或IIA期NSCLC患者,比较SBRT与3DCRT+IMRT后心血管结局与肿瘤侧别的关联。SBRT组左侧与右侧肿瘤的心血管复合结局风险无差异(HR 0.98;95%CI 0.84-1.15);3DCRT+IMRT组左侧肿瘤充血性心力衰竭(HR 1.23;95%CI 1.01-1.48)和经皮冠状动脉介入(HR 2.24;95%CI 1.12-4.47)风险更高。

要点

  • SBRT治疗左侧与右侧早期NSCLC的心血管事件风险相似。
  • 3DCRT+IMRT治疗左侧肿瘤充血性心力衰竭和经皮冠状动脉介入风险更高。
  • 左侧早期NSCLC患者SBRT可能较3DCRT+IMRT更安全。

核心结论

  • SBRT治疗左侧与右侧早期NSCLC的心血管事件发生率相似,而3DCRT+IMRT治疗左侧肿瘤者部分心脏事件发生率更高。
  • 研究提示SBRT可能较3DCRT+IMRT为左侧早期NSCLC提供更安全的选择,并强调放疗后长期随访的必要性。

研究设计与样本

  • 分析SEER登记数据库链接Medicare数据,纳入3,256例淋巴结阴性I或IIA期NSCLC患者,其中SBRT组1,506例、3DCRT+IMRT组1,750例。
  • 通过诊断代码识别心血管事件,比较左侧与右侧肿瘤的结局,并假设肿瘤侧别随机且左侧肿瘤放疗野可能使心脏组织受量更高。
  • 采用Cox回归模型量化肿瘤侧别与结局的关联,中位随访2年。

主要发现

  • SBRT组任何心血管结局的风险按肿瘤侧别均无差异,心血管复合结局比较左侧 vs 右侧肿瘤的HR为0.98(95%CI 0.84-1.15)。
  • 3DCRT+IMRT组左侧肿瘤充血性心力衰竭风险更高(HR 1.23;95%CI 1.01-1.48)。
  • 3DCRT+IMRT组左侧肿瘤经皮冠状动脉介入风险更高(HR 2.24;95%CI 1.12-4.47)。

临床怎么用

  • 对左侧早期NSCLC患者选择放疗方式时,可考虑SBRT以降低选择性心脏事件风险。
  • 接受3DCRT+IMRT的左侧早期NSCLC患者需关注充血性心力衰竭和经皮冠状动脉介入风险。
  • 放疗后应进行长期随访以监测心血管结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term risk of cardiovascular outcomes from either stereotactic body radiation therapy (SBRT) or three-dimensional conformal radiation therapy (3DCRT) plus intensity-modulated radiation therapy (IMRT) to treat early stage non-small cell lung cancer (NSCLC) is largely unknown. As continued adoption of SBRT accelerates, it is important to delineate unforeseen cardiovascular risks associated with treatment. RESEARCH QUESTION: Does the long-term risk of cardiovascular outcomes for patients with early stage NSCLC treated with either SBRT or 3DCRT plus IMRT differ by tumor laterality? STUDY DESIGN AND METHODS: Data from the Surveillance, Epidemiology, and End Results registry linked to Medicare was analyzed to identify a sample of 3,256 patients (1,506 treated with SBRT and 1,750 treated with 3DCRT plus IMRT) with node-negative stage I or IIA NSCLC. Cardiovascular events were identified using diagnosis codes, and outcomes were compared between left- and right-sided tumors. We assumed that tumor laterality was random and that the radiation field for left-sided tumors likely would result in greater dose to cardiac tissues. Cox regression models were fit to quantify the association of laterality on outcomes. RESULTS: Patients were followed up for a median of 2 years. Those treated with SBRT showed no difference in hazard of any cardiovascular outcomes by tumor laterality, including the cardiovascular composite (hazard ratio [HR] comparing left- vs right-sided tumors, 0.98; 95% CI, 0.84-1.15). In contrast, patients treated with 3DCRT plus IMRT showed a greater risk of congestive heart failure (HR, 1.23; 95% CI, 1.01-1.48) and percutaneous coronary artery intervention (HR, 2.24; 95% CI, 1.12-4.47). INTERPRETATION: Patients with left- vs right-sided early stage NSCLC showed similar rates of cardiovascular events when treated with SBRT. However, these patients also showed higher rates of select cardiac events when they were treated with 3DCRT plus IMRT. This study provides evidence that SBRT may provide a safer option over 3DCRT plus IMRT for patients with left-sided early stage NSCLC and underscores the need for long-term follow-up for patients treated with radiation therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Liu BY, Rehmani S, Kale MS, et al. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. Chest. 2022. PMID: 35063448. doi:10.1016/j.chest.2021.12.667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。